Proper Name: Coagulation Factor XIII A-Subunit (Recombinant)
Manufacturer: Novo Nordisk Inc
- Is indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A-Subunit deficiency.
FDA approves Tretten to treat rare genetic clotting disorder
12/23/2013 Press Release
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.